Form 8-K Jazz Pharmaceuticals For: Mar 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Jazz Pharmaceuticals (JAZZ) PT Lowered to $187 at BMO Capital
March 2, 2022 7:47 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $187.00 (from $202.00) while maintaining an Outperform rating following results.
The analyst commented, "4Q beat top- and bottom-line solidly, mainly driven by Epidiolex/Rylaze growth (also stocking) and continued progress with... More
